Literature DB >> 18397186

Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?

P L Lakatos1, I Altorjay, Y Mándi, L Lakatos, J Tumpek, A Kovacs, T Molnar, Z Tulassay, P Miheller, K Palatka, T Szamosi, S Fischer, J Papp, M Papp.   

Abstract

Antibodies against different microbial epitopes are associated with disease phenotype, may be of diagnostic importance and may reflect a loss of tolerance in Crohn's disease (CD). Recently, an association was reported between the presence of these antibodies and mutations in pattern receptor genes. Our aim was to investigate whether mutations in various genes other than NOD2/CARD15 or TLR4 associated with CD (NOD1/CARD4, DLG5 and DEFB1) may influence the presence of antibodies against bacterial proteins and carbohydrates in a Hungarian cohort of CD patients. Three hundred and seventy-six well-characterized, unrelated, consecutive CD patients (male/female: 191/185, age at onset: 29.1 +/- 12.9 years, duration: 7.9 +/- 11.7 years) were investigated. Sera were assayed for anti-Omp, anti-Saccharomyces cerevisiae antibodies (ASCAs) immunoglobulin (Ig) A and IgG, and antibodies against a mannan epitope of S. cerevisiae (gASCA), laminaribioside (ALCA), chitobioside (ACCA), and mannobioside (AMCA). NOD1/CARD4, DLG5 and DEFB1 variants were tested by polymerase chain reaction-restriction fragment length polymorphism, and DEFB1 was genotyped in a subgroup of 160 patients. Detailed clinical phenotypes were determined by reviewing the patients' medical charts. The carriage of DEFB1 20A variant alleles less frequently led to antiglycan positivity compared with patients without (29.6% vs 46.2%, OR: 0.49, 95% CI: 0.25-0.97), regardless of disease location or behavior. Similar tendency was observed for DEFB1 44G (present: 21.6% vs absent: 10.2%, P = 0.06) and ALCA. A gene or serology dosage effect was not observed. However, no association was found between the DEFB1 G52A, DLG5 R30Q, and NOD1/CARD4 E266K variants and any of the serology markers. We found that variants in human beta-defensin 1 gene are inversely associated with antiglycan antibodies, further confirming an important role for innate immunity in the pathogenesis of CD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397186     DOI: 10.1111/j.1399-0039.2008.01049.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

Review 1.  Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.

Authors:  Amit Kaul; Susan Hutfless; Ling Liu; Theodore M Bayless; Michael R Marohn; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

2.  Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon.

Authors:  Laurent Peyrin-Biroulet; Julia Beisner; Guoxing Wang; Sabine Nuding; Sajit Thottathil Oommen; Denise Kelly; Erika Parmentier-Decrucq; Rodrigue Dessein; Emilie Merour; Philipe Chavatte; Teddy Grandjean; Aude Bressenot; Pierre Desreumaux; Jean-Frédéric Colombel; Béatrice Desvergne; Eduard F Stange; Jan Wehkamp; Mathias Chamaillard
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

3.  Association of NOD1 (CARD4) insertion/deletion polymorphism with susceptibility to IBD: a meta-analysis.

Authors:  Wei-Guo Lu; Yan-Feng Zou; Xiao-Liang Feng; Feng-Lai Yuan; Yuan-Long Gu; Xia Li; Cheng-Wan Li; Cheng Jin; Jian-Ping Li
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

Review 4.  New serological biomarkers of inflammatory bowel disease.

Authors:  Xuhang Li; Laurie Conklin; Philip Alex
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

5.  Alpha-defensins (α-Defs) in Crohn's disease: decrease of ileal α-Def 5 via permanent methylation and increase in plasma α-Def 1-3 concentrations offering biomarker utility.

Authors:  E Cerrillo; I Moret; M Iborra; D Ramos; E Busó; L Tortosa; E Sáez-González; P Nos; B Beltrán
Journal:  Clin Exp Immunol       Date:  2018-01-10       Impact factor: 4.330

6.  Personalized management of IBD; is there any practical approach?

Authors:  Mohsen Norouzinia; Nosratollah Naderi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.